PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
نویسندگان
چکیده
Results We identified 6 children with AAV treated with rituximab (microscopic polyangeitis, n = 2, granulomatosis with polyangeitis, n = 2, unspecified vasculitis, n = 2). The age at onset ranged from 4 to 16 yrs. Treatment with rituximab consisted in 4 infusions of 375 mg/m; one patient received only 3 infusions. Mean duration of follow-up was 2.65 yrs. All patients achieved clinical remission after 12 months. One patient presented several relapses associated with B cell increase and was dependent on rituximab infusions. No severe adverse event had been reported.
منابع مشابه
PReS-FINAL-2322: Outcome of kidney transplantation in paediatric patients with ANCA associated glomerulonephritis: a single-center experience
Results Since 2000 there have been 6 paediatric patients transplanted with ANCA GN (5 MPA). 5 patients were ANCA positive at diagnosis: 1 c-ANCA, PR3 positive and 4 pANCA MPO positive. Age at ANCA GN diagnosis was 10.4 ± 4.3 (Mean ± SD) years (range 4.1 to 15.4). eGFR at diagnosis was 14.1 ± 6.2 ml/min/1.73 m. Renal biopsy category was crescentic in 4 and sclerotic in 2 by the new histopatholog...
متن کاملNew horizons for treatment of ANCA-associated vasculitides.
The field of ANCA-associated vasculitis therapy is currently undergoing probably the most momentous change since the effectiveness of adjunctive CYC to treat granulomatosis with polyangitiis (Wegener’s) was discovered in the early 1970s [1, 2]. Since 2001 [3], the numerous uncontrolled observations reporting the efficacy of the chimeric monoclonal anti-CD20 antibody rituximab against granulomat...
متن کاملAcute Respiratory Distress Syndrome and Posterior Reversible Encephalopathy Syndrome following Rituximab Therapy
The anti-CD20 monoclonal antibody rituximab is associated with rare but significant adverse events, notably posterior reversible encephalopathy syndrome (PRES) and acute respiratory distress syndrome (ARDS). We report a case of concomitant ARDS and PRES developing after rituximab therapy for treatment of cryoglobulinaemic vasculitis. There are 7 reported cases of PRES complicating rituximab use...
متن کاملRituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
BACKGROUND B-cell depletion with rituximab, a chimeric anti-CD20 antibody, is a novel treatment for refractory and relapsing ANCA-associated small-vessel vasculitis. Data are limited and most reports describe single patients or small numbers of patients followed prospectively. METHODS We report a single-centre experience with 15 patients who received rituximab for refractory or relapsing ANCA...
متن کاملRecommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
OBJECTIVES To perform a literature review and develop recommendations for the use of rituximab in ANCA-associated vasculitis. METHODS A committee of experts (five rheumatologists, five nephrologists and one paediatrician) conducted a modified Delphi exercise to identify five topics for a systematic literature search. The evidence was then reviewed, categorized according to international crite...
متن کامل